Articles

Low Testosterone Timeline

Articles

Low Testosterone Timeline


Story Highlights

1935

Discovery

Isolated testosterone is synthesized and introduced to treat hypogonadism.

 

1953

Hypogonadism Therapy

FDA approves Delatestryl to treat conditions associated with a deficiency or absence of testosterone, primarily known as hypogonadism. It is the only condition for which testosterone replacement therapy (TRT) is approved by the FDA. By 2010, the agency has approved at least eight more drugs — Testopel, Depo-Testosterone, Androderm, AndroGel, Testim, Striant, Axiron and Fortesta – to treat the uncommon condition.

1999

New Disease Penned

Big Pharma, in an attempt to persuade men and their doctors that there is a new condition termed “Low T” or “Andropause,” which medical critics say is simply the aging process, engages in direct-to-consumer advertising and physician education programs to expand the market for the drugs.

 

2000

Self Diagnosis

A geriatrics doctor at the St. Louis University School of Medicine develops a quiz in exchange for a $40,000 grant designed to help men self-diagnose whether they need testosterone. The quiz is featured on AndroGel’s website and TRT sites.

 

 

The FDA warns AbbVie for the second time that claims for AndroGel suggesting that the product is indicated for men with “age-associated hypogonadism” or “Andropause” are misleading.

 

2003

Blowing the Whistle

Federal whistleblower suit against AndroGel alleges that the company made millions by marketing testosterone drugs in the U.S. for conditions not approved by the FDA, offered kickbacks to physicians to prescribe the drug, and trained them to misstate diagnoses so that Medicaid would pay for the medications.

 

2006

Millions in Sales

AndroGel sales reach $300 million.

 

 

 

 

2007

Dosing Up

More than 100 million doses of testosterone are prescribed.

 

 

 

 

2010

Unapproved Uses

FDA warns Auxilium’s predecessor, Slate, that its “Reclaim Your Life” marketing campaign for Testopel is misleading because it promotes “unapproved uses of Testopel.”

 

2011

Risky Business

Nearly one in 25 men in their 60s are taking testosterone.

 

 

 

Kansas resident Robert Cripe suffers a spinal stroke and is paralyzed. He sues Androgel, alleging it’s the cause. He later becomes one of thousands of men suing testosterone manufacturers.

 

 

 

2012

Advertising Blitz

Drug makers spend more than $100 million to advertise testosterone products and sales reach $2 billion. The Colbert Report takes industry to task.

 

2013

A New Day

Axiron commercial by Grey New York entitled “A New Day” wins a bronze medal at the DTC National Advertising Awards.

 

 

 

‘Uncontrolled Experiment’

The Journal of the American Medical Association publishes scathing article on testosterone prescriptions calling Low T “[a] mass, uncontrolled experiment, which invites men to expose themselves to the harms of a treatment unlikely to fix problems which they may not really have.”

 

2014

Alarming Health Risks

Sales of TRT drugs top $2 billion, and there are more than 6.5 million prescriptions written.

 

 

 

Lawsuits against drug companies start to mount. In one, Ohio-based health insurer Medical Mutual asserts that the major TRT manufactures colluded in a “decade-long deceptive marketing scheme to transform the male aging process into a curable disease” and concealed side effects.

 

 

Feds Issue Warning

The FDA announces it is requiring manufacturers of testosterone to include a warning about health risks, including pulmonary embolism.

 

2015

Disease Mongering Persists

The Journal of the American Geriatrics Society lambasts the mass marketing and permissive prescribing of testosterone as “disease mongering.”

 

 

FDA Safety Alert

FDA issues a safety announcement, specifically noting that “prescription testosterone products are approved only for men who have low testosterone levels caused by certain medical conditions” and calls on drug makers to conduct clinical trials of testosterone products marketed to older men.

 

D-T-C Advertising Questioned

The American Medical Association votes in favor of a ban on direct-to-consumer drug advertising. Said AMA Board Chair Patrice A. Harris: “Today’s vote in support of an advertising ban reflects concerns among physicians about the negative impact of commercially-driven promotions….”

 

2016

Lawsuits Mount

The first bellwether trials of the more than 5,000 lawsuits filed against manufacturers will begin in the fall with AbbVie as the defendant. Big Pharma, is keeping close watch on cases and a possible First Amendment defense – as used in Amarin Pharma’s complaint against the FDA.

 

The Marketing Continues


You Might Be Interested In

Fisher Investments

Ad Alert

Fisher Investments

Unearthing the fees that Fisher charges but doesn’t disclose in some of its TV ads.